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Replication protein A (RPA) is a eukaryotic single-stranded DNA binding protein that is essential for
DNA replication, repair, and recombination, and human RPA interacting protein a (hRIPa) is the
nuclear transporter of RPA. Here, we report the regulatory role of hRIPa protein in cell proliferation.
Western blot analysis revealed that the level of hRIPawas frequently elevated in cervical tumors tis-
sues and hRIPa knockdown by siRNA inhibited cellular proliferation through deregulation of the
cell cycle. In addition, overexpression of hRIPa resulted in increased clonogenicity. These results
indicate that hRIPa is involved in cell proliferation through regulation of RPA transport.
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Replication Protein A (RPA) is a single-stranded DNA (ssDNA)
binding protein composed of three subunits, RPA1 (70 kDa), RPA2
(32 kDa), and RPA3 (14 kDa) [1]. RPA interacts tightly with ssDNA
to facilitate its stabilization and plays an essential role in multiple
processes of DNA metabolism, including DNA replication, DNA
recombination, and DNA repair [2,3]. RPA is also associated with
the proteins that regulate DNA metabolism and the checkpoint
pathway [4–6]. The ssDNA binding activity of RPA is localized to
the RPA1 (70 kDa) subunit [7,8].
Nuclear localization signal (NLS)-containing proteins are im-
ported into the nucleus by interacting with the heterodimer of
importin a and importin b, and importin a is the adaptor molecule
that links NLS-containing proteins and importin b [9,10]. Similarly,
RPA interacting protein a (RIPa) has been identiﬁed as an adaptor
molecule that links RPA and importin b, and the RIPa-importin b
complex can transport RPA into the nucleus [11,12]. Initially, xeno-
pus RIPa gene (xRIPa) was cloned, and subsequently hRIPa, the
human orthologue of xRIPa, was identiﬁed. Reverse transcrip-
tion-polymerase chain reaction (RT-PCR) analyses revealed thatchemical Societies. Published by E
sity, Division of Biological
yun, Wonju City 220-100,the hRIPa gene has many splice isoforms, and hRIPa and its splice
isoform, hRIPb, are expressed; however, a microscopy study
showed their subcellular localizations are distinctive [12,13]. hRI-
Pa transports RPA into the nucleus by shuttling between the cyto-
plasm and nucleus while hRIPb is localized in promyelocytic
leukemia (PML) nuclear bodies [12].
Recently, several studies have focused on the role of RPA in tu-
mor development. The level of RPA expression is elevated in tu-
mors, including breast and colon cancers, suggesting RPA is
potentially useful as a prognostic indicator and therapeutic target
[14,15]. Knockdown of RPA expression results in a high level of
spontaneous DNA damage, and the targeted inhibition of RPA re-
sults in cytotoxicity, suggesting that a proper level of RPA is re-
quired for genomic stability [16]. In addition, mutation in the
RPA1 DNA binding domain results in a DNA repair defect, and mice
containing this mutation have shortened life spans and elevated
cancer rates [17,18].
The growth response elicited by the plant hormone gibberellin
induces the expression of RPA1, and RPA mRNA peaks at the G1/S
phase boundary in yeast [19]. Similarly, rapidly growing cells, such
as tumor cells, express a higher level of RPA protein [14,15]. How-
ever, there is no previous study of hRIPa in this respect. Here, we
report the regulatory role of hRIPa protein in cell proliferation.
Western blot analysis revealed that the level of hRIPa was fre-
quently elevated in cervical tumors tissues. Knockdown of hRIPa
resulted in the deregulation of cell cycle and induced cell death.lsevier B.V. All rights reserved.
3754 S. Namkoong et al. / FEBS Letters 586 (2012) 3753–3760In addition, the lack of hRIPa resulted in the accumulation of DNA
mutations. The data from this study collectively indicate that hRI-
Pa is involved in cell proliferation by regulating RPA transport.
2. Materials and methods
2.1. Cell culture, transfection, and cell proliferation assay
HeLa cells were grown in DME medium supplemented with 10%
fetal bovine serum.TransfectionsofHeLa cellswere conductedusing
Lipofectamine reagent (Invitrogen, Carlsbad, CA) in accordancewith
the manufacturer’s instructions. Cell growth was measured using
the [4,5-dimethylthiazol-2-yl]-2,5-diphenyltrazolium bromide
(MTT) assay according to previously described methods [20]. Cells
were seeded in a 24-well plate and then transfected with the plas-
mids. After 48 h, cell proliferation was examined by MTT assay. For
cell cycle analysis, transfected cells were washed with phosphate
buffered saline (PBS) and ﬁxed with 70% ethanol. After centrifuga-
tion, cells were washed and resuspended in PBS containing 50 lg/
ml propidium iodide (PI) and 10 mg/ml RNase A (Sigma, St. Louis,
MO). Cells were analyzed in a FACSCalibur (Beckton-Dickinson,
Mountain View, CA). At least 10,000 cells per samplewere analyzed.
2.2. RNA interference of hRIPa and RPA
Small interfering RNA (siRNA) was purchased from ST PHARM
(Seoul, Korea). The nucleotide sequence for hRIPa siRNA #1 was
50-CCA CUC AUC UGU CCU GUA UTT-30 and for hRIPa siRNA #2
was 50-UCA AGA GGU GAU GGA AGA ATT-30. The nucleotide se-
quence for RPA siRNA was 50-AAC UGG UUG ACG AAA GUG GUG-
30 as previously described [16]. Transfections of siRNA into HeLa
cells were conducted using Lipofectamine RNAiMAX reagent
(Invitrogen) in accordance with the manufacturer’s instructions.
2.3. Semi-quantitative RT-PCR
For semi-quantitative RT-PCR, cells were harvested and RNAwas
extracted using Trizol (Invitrogen) in accordancewith themanufac-
turer’s instructions, and subjected to reverse transcription-PCR (RT-
PCR). hRIPamRNA was ampliﬁed using the 50 primer CAG AAG CTT
CGT GCC TGT TTA G and the 30 primer CTA GAG GAT CAC AGC CCA
AGT ATC. hRIPb mRNA was ampliﬁed using the 50 primer GAG TAT
GAG AAG AGC TTG CAG TTT G and the 30 primer TAT CAC AGG CAT
GAG ATG GG. Input RNA was normalized via the ampliﬁcation of
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) RNA.
2.4. Western blotting
The frozen tissues were homogenized in cell lysis buffer
(150 mM NaCl, 50 mM Hepes (pH 8.0), 0.5% Nonidet P-40) contain-
ing a protease inhibitor mixture (Roche Diagnostics). Western blot
detection was performed with a 1:2000 or 1:5000 dilution of pri-
mary antibody and an EZ-Western Detection Kit (Dogen, Seoul,
Korea). The images were acquired using Chemidoc-it 410 imaging
system (UVP, Upland, CA). Human cervical cancer and normal cer-
vix tissues were obtained from Chung-Ang University with the ap-
proval of the Institutional Review Board. Antibody for hRIPa was
purchased from Sigma and antibody for PARP-1 was from Santa-
cruz (Santacruz, CA). Antibody for RPA was generously provided
by B. Stillman [21].
2.5. Immunoﬂuorescence and confocal microscopy
Cells were grown on sterilized glass coverslips, ﬁxed with 4%
paraformaldehyde, and blocked with 10% goat serum in PBS. Cellswere stained with 1:500-diluted primary antibody in PBS and then
reacted with 1:1000-diluted Alexa 488-conjugated or Alexa 568-
conjugated secondary antibody (Invitrogen). Finally, slides were
washed three times with PBS and mounted in mounting medium
(Vector, Burlingame, CA). Antibody for gamma H2AX was pur-
chased from Cell Signaling Technology (Beverly, MA). Images were
captured with a Carl Zeiss LSM710 confocal microscope (Germany).
2.6. Clonogenic assay
HeLa cells were plated in six-well plates and transfected with
vector (pcDNA3.1), hRIPa (pcDNA3.1/hRIPa), or hRIPb
(pcDNA3.1/hRIPb). Two days later, the transfected cells were
grown for 20 days under 1 mg/ml G418 selection. The cells were
ﬁxed with methanol and stained with crystal violet. Multilayered
colonies were deeply stained, and the number of deeply stained
colonies was counted for further analysis.
3. Results
3.1. Upregulation of hRIPa protein in cervical tumor cells
Maintenance of genomic stability is required for cell survival
and proliferation, and the proteins involved in DNA metabolism
are necessary for genomic stability. Because DNA metabolism is
activated during cell proliferation, the level of RPA is often elevated
in rapidly growing cells, such as tumor cells [14,15]. Because hRIPa
is the major nuclear transporter of RPA, we investigated whether
the level of hRIPa is elevated in tumor cells. First, we examined
hRIPa protein expression in normal cervixes and cervical tumors
by Western blot analysis. The level of hRIPa protein expression
was clearly increased in 10 out of 17 cervical tumor samples rela-
tive to normal tissues (Fig. 1A). Next, we examined the level of RPA
expression, and RPA expression was also upregulated in tumors. In
particular, the RPA level was signiﬁcantly correlated with the hRI-
Pa level, suggesting RPA expression is closely linked with hRIPa
expression (Fig. 1B). These results indicate that hRIPa protein, as
well as RPA, is upregulated in tumor cells.
3.2. hRIPa expression is elevated during cell cycle
Because the cervical tumor cells expressed a high level of hRIPa
protein, we hypothesized that hRIPa is upregulated in rapidly
growing cells. To test our hypothesis, we examined the level of hRI-
Pa expression in the serum-starved cells. When cells are subjected
to serum-depleted medium, the cell proliferation rate is lowered
and the cell cycle is arrested in G1 phase. HeLa cells were main-
tained in serum-deﬁcient medium for 24 h, and cells were stimu-
lated with 20% FBS. While the level of hRIPa was relatively low,
serum stimulation induced the expression of hRIPa, suggesting
that the hRIPa level is related to cell proliferation (Fig. 1C). Next
we tracked hRIPa expression throughout the cell cycle. HeLa cells
were synchronized using the double thymidine block method,
and the synchronized cells were harvested at the indicated time
for further analysis (Fig. 1D). Western blot with anti-hRIPa anti-
body revealed that the level of hRIPa expression was elevated sig-
niﬁcantly from G2 phase (9 h after thymidine removal), and it
continued through to G1 (10.5 h and 12 h after thymidine removal)
(Fig. 1E and F). The quantitative data showed the level of RPA was
slightly increased at 10.5–12 h after thymidine removal, however
the difference did not reach the statistical signiﬁcance (Fig. 1E
and F). These results indicate that the level of hRIPa is increased
during the speciﬁc cell cycle, and hRIPa expression is elevated in
the rapidly growing cells, which progress through the cell cycle
rapidly.
Fig. 1. The level of hRIPa is often elevated in tumor cells. (A) The level of hRIPa was elevated in human cervical tumor cells. Normal cervixes and cervical tumors were
homogenized and equal amounts of protein were used for Western blot analysis. hRIPa expression was assessed by Western blots with anti hRIPa antibody. (B) Signiﬁcant
correlation of RPA and hRIPa protein. The levels of RPA and hRIPa protein were quantiﬁed and combined for analysis. (C) Induction of hRIPa expression by serum stimulation
after serum starvation. HeLa cells were incubated without serum for 24 h and stimulated to proliferate by addition of fetal bovine serum (FBS). Cells were collected, and an
equal amount of cell lysates was subject to Western blot with anti-hRIPa antibody. (D) Cell cycle analysis of HeLa cell synchronization. HeLa cells were synchronized by the
thymidine double block method. After thymidine removal, HeLa cells were collected at the indicated times and analyzed by ﬂow cytometry. (E) The level of hRIPa expression
was elevated signiﬁcantly from G2 phase (9 h after thymidine removal), and it continued through to G1 (10.5 h and 12 h after thymidine removal). The synchronized cells
were harvested, and the cell lysates were analyzed by Western blot. (F) The cell cycle analysis was repeated three times, and the levels of hRIPa and RPA were quantiﬁed.
Asterisk indicates the statistical signiﬁcance (P < 0.05, versus 0 h).
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Since the upregulation of hRIPa is observed in cancer cells and
rapidly growing cells, we hypothesized that the level of hRIPa is re-
lated to cell proliferation. In order to test our hypothesis, we exam-
ined the effect of hRIPa knockdown by siRNA. Because the main
function of hRIPa is the transport of RPA, we additionally knocked
down RPA to compare its effects. Two different hRIPa siRNAs were
designed against different regions of hRIPa mRNA to target both
hRIPa and hRIPb mRNA (Fig. 2A). Chemically synthesized siRNA
against either hRIPa (hRIPa siRNA) or RPA (RPA siRNA) was tran-
siently transfected into the HeLa cervical cancer cell line. HeLa cells
expressed mainly hRIPa protein, and hRIPb was barely detected
(Fig. 2B and Supplementary Fig. 1). Forty-eight hours after trans-
fection, hRIPa siRNA transfection almost completely abrogated
hRIPa expression, and RPA siRNA also efﬁciently knocked down
RPA expression (Fig. 2B). We compared the protein expression of
hRIPa and RPA, and higher expression of hRIPa protein was repeat-
edly observed in RPA siRNA transfected cells (Fig. 2B and C). RPA
siRNA transfection increased hRIPa expression up to 3.5-fold, andthe increase of hRIPa protein was still observed at 96 h after trans-
fection (Supplementary Fig. 2). To conﬁrm our results, a variable
amount of RPA siRNA (1, 5, 20, 50 pmol) was transfected into HeLa
cells and hRIPa expression increased in a dose dependent manner
(Fig. 2D). Next, we attempted to examine whether the upregulation
of hRIPa is transcriptionally increased upon RPA knockdown. HeLa
cells were transfected with either hRIPa siRNA or RPA siRNA, and
RT-PCR analysis with hRIPa or hRIPb speciﬁc primers was per-
formed. As we expected, RT-PCR analysis revealed that hRIPa siR-
NA efﬁciently silenced both hRIPa and hRIPb mRNA (Fig. 2E).
However, the level of hRIPa mRNA was not elevated upon RPA
knockdown. This result excluded the possibility of a transcriptional
increase of hRIPa by RPA knockdown.
3.4. Knockdown of hRIPa blocks RPA transport
Because hRIPa is responsible for the transport of RPA into the
nucleus, we examined whether the knockdown of hRIPa blocks
RPA transport. HeLa cells were transiently transfected with either
non-speciﬁc (NS) siRNA or hRIPa siRNA, and cells were immuno-
Fig. 2. Knockdown of hRIPa by siRNA. (A) Schematic diagrams of hRIPa mRNA structure and hRIPa siRNA (#1, #2) positions. Exons (E1–E7) and untranslated regions (UTR)
are indicated. The hRIPa gene can encode hRIPa and hRIPb by alternative splicing, and the protein products are shown as a solid bar. The speciﬁc primers for RT-PCR for hRIPa
and hRIPb are shown as an arrow and PCR products as a dotted line. (B, C) Knockdown of hRIPa and RPA expression. HeLa cells were transfected with non-speciﬁc (NS) siRNA
or siRNA against either hRIPa or RPA. Cells were collected and equal amounts of cell lysates were subject to Western blot with the indicated antibody. The density of hRIPa
protein was quantitated and plotted on the bar graph. The experiments were repeated independently three times and the standard deviation is shown. (D) RPA knockdown
increased hRIPa expression in a dose-dependent manner. A various amount of RPA siRNA (0, 1, 5, 20, 50 pmol) was transfected into HeLa cells, and the expression of hRIPa
was examined by Western blot. (E) The mRNA transcripts of hRIPa and hRIPb were analyzed by RT-PCR using total RNA from HeLa cells that were transfected with the
indicated siRNA.
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the localization of RPA was mainly nuclear in the non-speciﬁc siR-
NA transfected cells, the knockdown of hRIPa resulted in cytoplas-
mic localization of RPA (Fig. 3A). A low level of RPA in the nucleus
was detected in hRIPa siRNA transfected cells and the proportion
of the cells with nuclear RPA was quantiﬁed (n = 100, three inde-
pendent experiments) and the graph is shown (Fig. 3B). In addition,
knockdown of RPA did not affect the localization of hRIPa, and the
elevated level of hRIPa expression was also detected on confocal
immunoﬂuorescence microscopy (Fig. 3A). These results indicate
that hRIPa knockdown decreases nuclear RPA by blocking RPA
transport.
3.5. Knockdown of hRIPa results in the loss of RPA function and
interferes with cell proliferation, the cell cycle, and DNA repair
Because RPA was not properly transported into the nucleus fol-
lowing the transfection of hRIPa siRNA, we hypothesized that the
effect of hRIPa knockdown is quite similar to the effect of RPA loss.
Previous studies have reported that RPA knockout results in DNA
replication defects and spontaneous DNA damage [16,22]. First,
we examined the effect of hRIPa knockdown on cellular prolifera-
tion. HeLa cells were transfected with non-speciﬁc hRIPa or RPA
siRNA, and cell proliferation was measured by MTT assay at 48 h
and 96 h post-transfection. Knockdown of both hRIPa and RPA re-
sulted in decreased cell survival. A slight decrease of cellular pro-liferation was observed at 48 h post-transfection and a dramatic
decrease was observed at 96 h post-transfection (Fig. 4A). Micros-
copy showed that both hRIPa and RPA deﬁcient cells were rounded
and detached from the bottom at 48 h (Fig. 4B). At 96 h post-trans-
fection, knockdown of hRIPa, as well as RPA, completely abolished
the cells viability (Supplementary Fig. 3). These results indicate
that the inhibitory effect of hRIPa knockdown on the cell replica-
tion is analogous to the effect of RPA knockdown.
Next, we examined the impact of hRIPa knockdown on cell cy-
cle progression. HeLa cells were transfected with NS siRNA, hRIPa
siRNA, or RPA siRNA. At 48 h or 96 h post-transfection, cells were
stained with propidium and ﬂow cytometric analysis was per-
formed. As reported previously [16], transfection of RPA siRNA re-
sulted in G2/M arrest at 48 h post-transfection and transfection of
hRIPa siRNA also increase the population of G2/M (Fig. 4C). We fur-
ther examined the cell cycle by knockdown of hRIPa or RPA at 96 h
post-transfection. Transfection of hRIPa siRNA resulted in the loss
of the G1 population and an increase of the sub-G1 population,
suggesting that the transfected cells underwent apoptosis
(Fig. 4C). To conﬁrm the apoptosis induction by knockdown of hRI-
Pa or RPA at 96 h post-transfection, we measured the cleavage of
PARP (poly ADP-ribose polymerase). Cleaved PARP is the reliable
indicator of apoptosis [23]. Brieﬂy, HeLa cells were transfected
with either hRIPa siRNA or RPA siRNA and we performed Western
blot with anti-PARP antibody. The level of cleaved PARP was in-
creased by knockdown of hRIPa or RPA at 96 h post-transfection
Fig. 3. Knockdown of hRIPa blocked RPA transport. (A) HeLa cells were transfected with NS siRNA, hRIPa siRNA, or RPA siRNA. At 48 h post-transfection, cells were ﬁxed and
stained with a rabbit polyclonal anti-hRIPa (green) antibody and a mouse monoclonal anti-RPA antibody (red). Nuclei were stained with DAPI (blue) and cells were analyzed
by confocal microscope. (B) The proportion of the cells with nuclear RPA was quantiﬁed (n = 100). Each experiment was repeated three times.
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served deregulation of the cell cycle by hRIPa knockdown was
comparable to the phenotype of RPA knockdown.
Because a previous study reported that an insufﬁcient level of
RPA caused spontaneous DNA damage [16], we hypothesized that
the lack of hRIPa would result in spontaneous DNA damage by
eliminating nuclear RPA. HeLa cells were transfected with NS siR-
NA, hRIPa siRNA, or RPA siRNA, and the cells were stained with
anti-phospho H2AX antibody at 48 h post-transfection. Phosphor-
ylation of histone H2AX is an early and sensitive marker of DNA
damage in eukaryotic cells [24]. While the transfection of NS siRNA
showed weak staining of phospho-H2AX, the transfection of hRIPa
siRNA resulted in intense staining of phopho-H2AX (Fig. 4E). The
immunoreactivity against phospho-H2AX of the hRIPa knockdown
was comparable to that of the RPA knockdown. To conﬁrm our re-
sults, the level of H2AX phosphorylation was examined byWestern
blot with anti-phospho H2AX antibody, and the level of phospho
H2AX was increased in both hRIPa and RPA deﬁcient cells indicat-
ing that an insufﬁcient level of hRIPa caused spontaneous DNA
damage (Fig. 4F). These results collectively indicate that hRIPa
knockdown is comparable to RPA knockdown.
3.6. Overexpression of hRIPa results in increased clonogenicity
Because hRIPa knockdown inhibited cell proliferation, we at-
tempted to examine whether the overexpression of hRIPa is posi-
tively involved in cell proliferation. We assessed the effect of hRIPa
overexpression on cell proliferation by clonogenic assay. HeLa cells
were transfected with vector (pcDNA3.1), hRIPa (pcDNA3.1/hRI-
Pa), or hRIPb (pcDNA3.1/hRIPb), and the transfected cells were
grown for 20 days under G418 selection. When colonies were visu-
alized, cells were ﬁxed and stained with crystal violet. While the
colonies of vector-transfected cells were weakly stained, the colo-
nies of hRIPa-transfected cells were deeply stained, indicating
multilayered growth (Fig. 5A). When we observe the colony bymicroscopy, and the colony sizes of hRIPa were bigger than those
of the vector, suggesting that hRIPa expression contributes to cell
survival and proliferation (Fig. 5B and C). In addition, the colony of
hRIPbwas not strong like the colony of hRIPa (Fig. 5A and B). These
results indicate that hRIPa is positively involved in cell survival
and proliferation.
4. Discussion
In this study, we demonstrated the positive role of hRIPa pro-
tein in cell proliferation. Western blot analysis revealed that the le-
vel of hRIPawas frequently elevated in cervical tumors tissues, and
hRIPa protein is required for cellular proliferation. In order to
examine the effect of hRIPa loss on cell proliferation, we used a
knockdown system with siRNA against hRIPa, and the expression
of hRIPa was efﬁciently blocked by hRIPa siRNA. The knockdown
of hRIPa resulted in both cell cycle deregulation and the accumu-
lation of DNA damage, indicating that hRIPa is required for cell cy-
cle progression. Furthermore, the overexpression of hRIPa resulted
in increased clonogenicity, suggesting that hRIPa protein is in-
volved in cell proliferation.
Because hRIPa is reported to transport RPA into the nucleus, we
hypothesized that the loss of hRIPawould interfere with RPA func-
tion. For this reason, we additionally examined the effect of RPA
knockdown to compare its effects. In the middle of our experi-
ments, we obtained unexpected results from RPA knockdown.
The level of hRIPa protein was aberrantly elevated by RPA knock-
down, while the level of hRIPa mRNA was not signiﬁcantly chan-
ged. From these results, we speculate that hRIPa is a disposable
protein for the transport of RPA. To put it brieﬂy, the life of hRIPa
can be decreased by extensive RPA transport, and blocking RPA
transport may extend the half-life of hRIPa. In addition, the in-
crease of hRIPa protein by RPA knockdown can also be interpreted
as a negative feedback mechanism. When the level of RPA protein
is lowered by siRNA or another signal, the cell may want to
Fig. 4. The effect of hRIPa knockdown was comparable to the effect of RPA knockdown. (A) Transfection of hRIPa siRNA inhibited cellular proliferation. HeLa cells were
transfected with NS siRNA, hRIPa siRNA, or RPA siRNA, and cell viability was assessed by MTT assays at 48 h or 96 h post-transfection. (B) Cell morphology was photographed
under microscope at 48 h after transfection and representative pictures are shown. (C) Flow-cytometric analysis of siRNA-transfected cells. NS siRNA, hRIPa, or RPA siRNA
transfected cells were stained with propidium iodide and analyzed by ﬂow cytometry at 48 h or 96 h post-transfection. (D) Apoptosis induction by knockdown of hRIPa or
RPA at 96 h post-transfection. The cleaved PARP was determined by Western blot. (E) Accumulation of spontaneous DNA damage by hRIPa knockdown at 48 h post-
transfection. HeLa cells were transfected with the indicated siRNA, and the cells were stained with anti-phospho-H2AX antibody. Nuclei were stained with DAPI (blue) and
cells were analyzed by confocal microscope. (F) The level of H2AX phosphorylation was examined by Western blot at 48 h post-transfection. Equal amounts of cell lysates
were subject to Western blot with the indicated antibody.
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transporter proteins. The regulation of hRIPa expression is regu-
lated at the post-transcriptional level, such as protein stability,
since the level of hRIPa mRNA was not affected by RPA knock-
down. In this study, we did not study the mechanism of hRIPa deg-
radation, which is potentially important for hRIPa regulation.
Therefore, further study is required to reveal the mechanism of
hRIPa degradation.
Because active DNA replication occurs in rapidly growing cells,
such as tumor cells, these cells require an adequate supply of RPA.
We demonstrated that the level of hRIPa protein was often ele-
vated in tumors, and the level of hRIPawas signiﬁcantly correlated
with the level of RPA protein, suggesting that hRIPa is upregulated
in tumor cells to accelerate RPA transport. In addition, the serum
addition after serum starvation induced the expression of hRIPa
protein, and the cell cycle analysis showed that the level of hRIPa
expression was elevated signiﬁcantly from G2 phase, and it contin-
ued through to G1. These results collectively indicate that rapidly
growing cells express higher levels of hRIPa protein. Since the tu-
mor cells generally replicate faster than normal cells, hRIPa ap-
pears to be elevated in tumor cells. It will be clinically valuableto study the relationship between the level of hRIPa and tumor
progression.
To examine the effect of hRIPa insufﬁciency, we used the siRNA
system to decrease hRIPa expression. hRIPa knockdown efﬁciently
blocked RPA transport, and the level of nuclear RPA protein was de-
creased. Hence, we assumed that the hRIPa knockdown would re-
sult in an outcome similar to RPA knockdown. Previous reports
have shown that RPA knockdown deregulates the cell cycle and in-
duces apoptosis [16]. In addition, RPA knockdown also interferes
with DNA repair, and DNA damage accumulates. For this reason,
we attempted to determine whether hRIPa knockdown would pro-
duce a similar outcome. As we expected, the loss of hRIPa showed
a similar phenotype, with deregulation of the cell cycle and accu-
mulation of DNA damage. These results conﬁrmed that hRIPa is a
major transporter of RPA. RIPa protein is not conserved in yeast,
and another transport protein is involved in RPA transport in yeast.
Therefore, it is possible that RPA has multiple transporter proteins
other than hRIPa. However, our results demonstrate that hRIPa is a
major transporter of RPA. If there were other proteins that have a
function similar to hRIPa, a lack of nuclear RPA could be compen-
sated for by other transporter proteins.
Fig. 5. hRIPa expression improved cell proliferation. (A) Clonogenic assays were carried out to assess the effects of hRIPa and hRIPb. HeLa cells were transfected with vector
(pcDNA3.1), hRIPa (pcDNA3.1/hRIPa) or hRIPb (pcDNA3.1/hRIPb), and the transfected cells were grown for 20 days under G418 selection before ﬁxation and staining with
crystal violet. (B) Light microscopy (200) showing close-up images of clonogenic assay. (C) The number of multilayered colonies was counted.
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they are hRIPb, hRIPc, and hRIPd1–3 [12,13]. Among hRIPa and
its isoforms, hRIPa and hRIPb are the major products; however,
their functions appear to be distinctive. hRIPb is rarely detected
in cervical tumor cells by Western blot, and the ectopic expression
of hRIPb does not increase clonogenicity. These results collectively
indicate the discrete function of hRIPa and hRIPb. Because hRIPa
and hRIPb share a majority of their nucleotide sequence, it is difﬁ-
cult to design an siRNA to silence only hRIPa or only hRIPb. We
repeatedly attempted to silence either hRIPa or hRIPb exclusively
by siRNA, but we were not successful. Further study will be re-
quired to characterize hRIPa and hRIPb in detail.
Several reports have shown that the level of RPA is increased in
tumor cells, and the inhibition of RPA function induces cell death.
For this reason, RPA is a potential target for cancer therapy. As we
showed in the RPA knockdown, the lack of RPA protein induces
apoptosis. Moreover, recent report showed that a small molecule
that inhibits the ssDNA binding activity of RPA induces cell death
suggesting the cellular function of function is the therapeutic target
for cancer treatment [25]. In the sameway, the level of hRIPa is often
elevated in tumor cells, the knockdown of hRIPa resulted in cell
death in our study. In this respect, hRIPa is a potentialmolecular tar-
get for cancer therapy, and inhibitors that interferewith hRIPa func-
tion can be used to induce apoptosis effectively. The development of
effective hRIPa inhibitors is needed for this purpose.
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